Filgrastim for the Promotion of Collateral Growth in Patients With CAD

Completed 50 enrolled Insel Gruppe AG, University Hospital Bern Swiss Heart Foundation · collab Swiss National Science Foundation · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study in humans with stable coronary artery disease (CAD) treatable by PCI (percutaneous coronary intervention) is to evaluate the safety and efficacy of subcutaneous delivery of recombinant granulocyte colony stimulating factor rG-CSF (Filgrastim, Neupogen®, Amgen Switzerland) with regard to the promotion of collateral growth.

Timeline

Start: 2004-11
Primary completion: 2007-12
Completion: 2007-12

Publications

Meier P, Gloekler S, de Marchi SF, Indermuehle A, Rutz T, Traupe T, Steck H, Vogel R, Seiler C. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation. 2009 Oct 6;120(14):1355-63. doi: 10.1161/CIRCULATIONAHA.109.866269. Epub 2009 Sep 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	filgrastim	Protein / enzyme biologic	10 ug/kg	Subcutaneous

Filgrastim for the Promotion of Collateral Growth in Patients With CAD

Summary

Timeline

Publications

Drugs

Indications